Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study

OBJECTIVE: Inhibiting sodium–glucose cotransporters (SGLTs) improves glycemic and cardiovascular outcomes in patients with type 2 diabetes (T2D). We investigated the differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and SGLT2 on multiple parameters. RESEARCH DESIGN AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Posch, Maximilian G., Walther, Niklas, Ferrannini, Ele, Powell, David R., Banks, Phillip, Wason, Suman, Dahmen, Raphael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472498/
https://www.ncbi.nlm.nih.gov/pubmed/35817022
http://dx.doi.org/10.2337/dc21-2166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472498/
https://www.ncbi.nlm.nih.gov/pubmed/35817022
http://dx.doi.org/10.2337/dc21-2166

Ejemplares similares